Novel mechanism of modulation at a ligand‐gated ion channel; action of 5‐Cl‐indole at the 5‐HT3A receptor
- 1 November 2016
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 173 (24) , 3467-3479
Abstract
Background and Purpose: The 5‐HT3receptor is a prototypical member of the Cys‐loop ligand‐gated ion channel (LGIC) superfamily and an established therapeutic target. In addition to activation via the orthosteric site, receptor function can be modulated by allosteric ligands. We have investigated the pharmacological action of Cl‐indole upon the 5‐HT3A receptor and identified that this positive allosteric modulator possesses a novel mechanism of action for LGICs.Experimental Approach: The impact of Cl‐indole upon the 5‐HT3receptor was assessed using single cell electrophysiological recordings and [3H]‐granisetron binding in HEK293 cells stably expressing the 5‐HT3receptor.Key Results: Cl‐indole failed to evoke 5‐HT3A receptor‐mediated responses (up to 30 μM) or display affinity for the [3H]‐granisetron binding site. However, in the presence of Cl‐indole, termination of 5‐HT application revealed tail currents mediated via the 5‐HT3A receptor that were independent of the preceding 5‐HT concentration but were antagonized by the 5‐HT3receptor antagonist, ondansetron. These tail currents were absent in the 5‐HT3AB receptor. Furthermore, the presence of 5‐HT revealed a concentration‐dependent increase in the affinity of Cl‐indole for the orthosteric binding site of the human 5‐HT3A receptor.Conclusions and Implications: Cl‐indole acts as both an orthosteric agonist and an allosteric modulator, but the presence of an orthosteric agonist (e.g. 5‐HT) is a prerequisite to reveal both actions. Precedent for ago‐allosteric action is available, yet the essential additional presence of an orthosteric agonist is now reported for the first time. This widening of the pharmacological mechanisms to modulate LGICs may offer further therapeutic opportunities.Keywords
This publication has 52 references indexed in Scilit:
- 5‐Chloroindole: a potent allosteric modulator of the 5‐HT3 receptorBritish Journal of Pharmacology, 2013
- Cysteine modification reveals which subunits form the ligand binding site in human heteromeric 5-HT3AB receptorsThe Journal of Physiology, 2011
- Extracellular Loop 2 of the Free Fatty Acid Receptor 2 Mediates Allosterism of a Phenylacetamide Ago-Allosteric ModulatorMolecular Pharmacology, 2011
- Agonist activation of α7 nicotinic acetylcholine receptors via an allosteric transmembrane siteProceedings of the National Academy of Sciences, 2011
- Agonists and Antagonists Bind to an A-A Interface in the Heteromeric 5-HT3AB ReceptorBiophysical Journal, 2010
- Single-Channel Kinetic Analysis for Activation and Desensitization of Homomeric 5-HT3A ReceptorsBiophysical Journal, 2009
- The 5-HT3 receptor – the relationship between structure and functionNeuropharmacology, 2009
- The L293 residue in transmembrane domain 2 of the 5-HT3A receptor is a molecular determinant of allosteric modulation by 5-hydroxyindoleNeuropharmacology, 2008
- RIC-3 Enhances Functional Expression of Multiple Nicotinic Acetylcholine Receptor Subtypes in Mammalian CellsMolecular Pharmacology, 2005
- GABAA receptor needs two homologous domains of the & beta;-subunit for activation by GABA but not by pentobarbitalNature, 1993